The app for independent voices
Viking Therapeutics Trading Higher on Lilly Partnership Speculation
VKTX running on reports of a potential $15B partnership with Eli Lilly. Miami Tier 1 name. $3.81B market cap. Zero debt. Current ratio 9.33x. Cash fortress.
Lilly has been the most aggressive acquirer this cycle. Centessa for $6.3B. Orna for $2.4B. Now circling Viking at $15B. The GLP-1/obesity space is the single hottest therapeutic area in pharma and VKTX has one of the most promising oral and injectable programs outside of Lilly and Novo.
Earnings April 22. Three weeks out. If this Lilly deal has legs, expect more headlines before that date.
This is the M&A snowball. Every deal makes the next one more urgent. Lilly isn't slowing down, they're accelerating.